Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma
Related Experiment Video
Updated: May 2, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
29.3K
Mehmet A N Sendur1, Sercan Aksoy2, Nuriye Yıldırım Özdemir1
1Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
Indian Journal of Pharmacology
|February 20, 2014
Abstract:
Bevacizumab is a recombinant humanized monoclonal antibody that selectively blocks the activity of vascular endothelial growth factor (VEGF) receptor and it is used in metastatic colorectal patients. We present here a case of fatal necrotizing fasciitis in a patient during bevacizumab treatment for colorectal cancer. In our review of the literature, necrotizing fasciitis was not reported before or during bevacizumab treatment.
